Drugs / Estradiol/norethindrone acetate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03204318 | Dec 2017 → Jun 2020 | endometriosis | Myovant Sciences GmbH | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Estradiol/norethindrone acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03204318 ↗ |
| Route | Oral | “Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.” NCT03204318 ↗ |